Info

XOMA Ltd. is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies. The Company’s lead product candidate is XOMA 052, a high affinity anti-IL-1 beta antibody with the potential to treat multiple inflammatory diseases of large unmet need. XOMA has multiple revenue streams and generates revenues from product royalties, technology licenses, development collaborations and biodefense contracts. The Company receives royalties on two approved products, Raptiva, which is marketed globally for the treatment of moderate-to-severe plaque psoriasis, and Lucentis, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration. XOMA has established on-going technology licensing programs for certain of its technologies, which have attracted licensees including Pfizer, Inc.(Source: 10-K)